

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Pharmaron Beijing Co., Ltd.**

**康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

## **NOTICE OF BOARD MEETING**

A meeting of the board of directors (the “**Board**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) will be held on Monday, March 30, 2026 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and considering the recommendation on payment of a final dividend, if any.

By order of the Board  
**Pharmaron Beijing Co., Ltd.**  
**Dr. Lou Boliang**  
*Chairman*

Beijing, the PRC  
March 16, 2026

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian as independent non-executive Directors.*